Evidence map›Paper›PMID 30682194›Full record

ArticlePloS one2019

Quadruplex-forming oligonucleotide targeted to the VEGF promoter inhibits growth of non-small cell lung cancer cells.

David Muench, Francine Rezzoug, Shelia D Thomas, Jingjing Xiao, Ashraful Islam, Donald M Miller, Kara C Sedoris

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

David MuenchDepartment of Immunobiology, University of Cincinnati, Cincinnati, Ohio, United States of America.ORCID 0000-0002-8723-3389
Francine RezzougJames Graham Brown Cancer Center, Department of Medicine, University of Louisville, Louisville, Kentucky, United States of America.
Shelia D ThomasJames Graham Brown Cancer Center, Department of Medicine, University of Louisville, Louisville, Kentucky, United States of America.ORCID 0000-0002-1892-3765
Jingjing XiaoJames Graham Brown Cancer Center, Department of Medicine, University of Louisville, Louisville, Kentucky, United States of America.
Ashraful IslamFaculty of Medicine, University of Tabuk, Tabuk, Saudi Arabia.
Donald M MillerJames Graham Brown Cancer Center, Department of Medicine, University of Louisville, Louisville, Kentucky, United States of America.ORCID 0000-0003-2467-0730
Kara C SedorisDepartment of Physiology, University of Louisville, Louisville, Kentucky, United States of America.
University of Louisville · USUniversity of Cincinnati · USUniversity of Tabuk · SA

Funding

PILOT PROJECT PROGRAMP30GM106396 · NIGMS · UNIVERSITY OF LOUISVILLE · PI MILLER, DONALD M. · 2013 to 2017
$5.4M
Common hTERT Promoter Mutations Represent a Novel Therapeutic TargetR21CA191663 · NCI · UNIVERSITY OF LOUISVILLE · PI MILLER, DONALD M. · 2016 to 2017
$368k
NCI NIH HHS R21 CA191663NIGMS NIH HHS P30 GM106396
6 · The paper itself

Abstract

backgroundVascular endothelial growth factor (VEGF) is commonly overexpressed in a variety of tumor types including lung cancer. As a key regulator of angiogenesis, it promotes tumor survival, growth, and metastasis through the activation of the downstream protein kinase B (AKT) and extracellular signal-regulated kinase (ERK 1/2) activation. The VEGF promoter contains a 36 bp guanine-rich sequence (VEGFq) which is capable of forming quadruplex (four-stranded) DNA. This sequence has been implicated in the down-regulation of both basal and inducible VEGF expression and represents an ideal target for inhibition of VEGF expression.

resultsOur experiments demonstrate sequence-specific interaction between a G-rich quadruplex-forming oligonucleotide encoding a portion of the VEGFq sequence and its double stranded target sequence, suggesting that this G-rich oligonucleotide binds specifically to its complementary C-rich sequence in the genomic VEGF promoter by strand invasion. We show that treatment of A549 non-small lung cancer cells (NSCLC) with this oligonucleotide results in decreased VEGF expression and growth inhibition. The VEGFq oligonucleotide inhibits proliferation and invasion by decreasing VEGF mRNA/protein expression and subsequent ERK 1/2 and AKT activation. Furthermore, the VEGFq oligonucleotide is abundantly taken into cells, localized in the cytoplasm/nucleus, inherently stable in serum and intracellularly, and has no effect on non-transformed cells. Suppression of VEGF expression induces cytoplasmic accumulation of autophagic vacuoles and increased expression of LC3B, suggesting that VEGFq may induce autophagic cell death.

conclusionOur data strongly suggest that the G-rich VEGFq oligonucleotide binds specifically to the C-rich strand of the genomic VEGF promoter, via strand invasion, stabilizing the quadruplex structure formed by the genomic G-rich sequence, resulting in transcriptional inhibition. Strand invading oligonucleotides represent a new approach to specifically inhibit VEGF expression that avoids many of the problems which have plagued the therapeutic use of oligonucleotides. This is a novel approach to specific inhibition of gene expression.

Indexed as

G-QuadruplexesPromoter Regions, GeneticA549 CellsCarcinoma, Non-Small-Cell LungDrug Delivery SystemsGene Expression Regulation, NeoplasticHumansLung NeoplasmsMAP Kinase Signaling SystemNeoplasm ProteinsOligonucleotidesVascular Endothelial Growth Factor ANeoplasm ProteinsOligonucleotidesVascular Endothelial Growth Factor AVEGFA protein, human

Identifiers

PMID30682194
PMCPMC6347295
OpenAlexW2911639198

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.